论文部分内容阅读
据第30届介入放射医学协会年会报道,一项有关射频技术切除(RFA)肺部恶性小肿瘤的多中心试验结果表明,采用RFA治疗NSCLC(非小细胞肺癌)患者的2年存活率可达91.5%。来自于意大利比萨大学放射医学副教授Riccar-do Lenconi博士报道说,结肠癌(CRC)患者转移性肺癌在接受射频治疗后,无癌症存活2年的患者比率为72%;在接受射频治疗的186个转移病灶中,完全被切除者173个,治疗成功率可达93%。Lenconi博士认为,目前外科手术仍是早期肺癌患者的首选方法,但对于手术或放疗禁忌的患者来说,RFA则可作为一种选择。
According to the 30th Annual Meeting of the Interventional Radiological Society, a multicenter trial of radiofrequency ablation (RFA) of small malignant lung tumors showed that 2-year survival rates for patients treated with RFA for NSCLC (non-small cell lung cancer) Up to 91.5%. Dr. Riccar-do Lenconi, an associate professor of radiology at the University of Pisa in Italy, reported that metastatic lung cancer in patients with colon cancer (CRC) had 72% of patients who survived 2 years without radiotherapy after radiofrequency ablation. Of the 186 patients who received radiofrequency ablation Metastatic lesions, totally resected 173, the success rate of up to 93%. Dr. Lenconi believes surgery is still the preferred method of early-stage lung cancer, but RFA is an option for patients with contraindications to surgery or radiotherapy.